(MGNX) MacroGenics - Ratings and Ratios
Antibodies, Cancer, Immunotherapy, Clinical Trials, Oncology
MGNX EPS (Earnings per Share)
MGNX Revenue
Description: MGNX MacroGenics
MacroGenics Inc (NASDAQ:MGNX) is a biotechnology company listed on the NASDAQ stock exchange. As a common stock, it represents ownership in the company. With a market capitalization of approximately $99.87 million USD, the companys valuation is relatively small, which can be a characteristic of companies in the biotechnology sector that are often in various stages of research and development.
The absence of a Price-to-Earnings (P/E) ratio, both current and forward, suggests that MacroGenics is not profitable, which is not uncommon for companies in the biotechnology industry that are investing heavily in research and development. The negative Return on Equity (RoE) of -59.84% indicates that the company is not generating profits from shareholder equity, aligning with the expectation that it is likely in a growth phase rather than a profitability phase.
Key economic drivers for MacroGenics include the progress of its drug pipeline, regulatory approvals, and the competitive landscape within the biotechnology industry. The companys financial health, including its cash burn rate and ability to secure funding, will be crucial in determining its ability to continue operations and invest in its R&D pipeline. Investors should monitor news related to clinical trial results, FDA approvals, and strategic partnerships, as these can significantly impact the stock price.
To evaluate the investment potential of MGNX, one should consider KPIs such as the advancement of its most promising drug candidates, the companys cash runway, and the overall market demand for its potential treatments. The volatility of the stock, as indicated by its Beta of 1.656, suggests that it is more volatile than the overall market, which can be a consideration for risk-averse investors. The average trading volume of 516,104 shares indicates a reasonable level of liquidity, making it easier for investors to buy and sell shares.
MGNX Stock Overview
| Market Cap in USD | 109m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2013-10-10 |
MGNX Stock Ratings
| Growth Rating | -74.7% |
| Fundamental | 13.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -56.1% |
| Analyst Rating | 3.56 of 5 |
MGNX Dividends
Currently no dividends paidMGNX Growth Ratios
| Growth Correlation 3m | 62.9% |
| Growth Correlation 12m | -80.6% |
| Growth Correlation 5y | -80.6% |
| CAGR 5y | -17.00% |
| CAGR/Max DD 3y | -0.18 |
| CAGR/Mean DD 3y | -0.48 |
| Sharpe Ratio 12m | -1.04 |
| Alpha | 0.15 |
| Beta | 0.545 |
| Volatility | 85.33% |
| Current Volume | 887.8k |
| Average Volume 20d | 912k |
| Stop Loss | 1.6 (-7.5%) |
| Signal | 1.54 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-36.4m TTM) > 0 and > 6% of Revenue (6% = 9.83m TTM) |
| FCFTA -0.29 (>2.0%) and ΔFCFTA 10.39pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 101.3% (prev 241.5%; Δ -140.2pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.29 (>3.0%) and CFO -72.1m <= Net Income -36.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.25 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (63.1m) change vs 12m ago 0.75% (target <= -2.0% for YES) |
| Gross Margin 86.78% (prev 82.72%; Δ 4.06pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 73.39% (prev 20.39%; Δ 53.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -37.60 (EBITDA TTM -26.9m / Interest Expense TTM 917.0k) >= 6 (WARN >= 3) |
Altman Z'' -19.75
| (A) 0.68 = (Total Current Assets 204.9m - Total Current Liabilities 39.0m) / Total Assets 245.4m |
| (B) -5.08 = Retained Earnings (Balance) -1.25b / Total Assets 245.4m |
| warn (B) unusual magnitude: -5.08 — check mapping/units |
| (C) -0.15 = EBIT TTM -34.5m / Avg Total Assets 223.3m |
| (D) -6.27 = Book Value of Equity -1.25b / Total Liabilities 198.8m |
| Total Rating: -19.75 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 13.13
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -73.72% = -5.0 |
| 3. FCF Margin -43.99% = -7.50 |
| 4. Debt/Equity 3.54 = -1.52 |
| 5. Debt/Ebitda -6.13 = -2.50 |
| 6. ROIC - WACC (= -41.55)% = -12.50 |
| 7. RoE -40.24% = -2.50 |
| 8. Rev. Trend -21.15% = -1.59 |
| 9. EPS Trend -15.33% = -0.77 |
What is the price of MGNX shares?
Over the past week, the price has changed by +4.85%, over one month by +13.82%, over three months by +26.28% and over the past year by -47.58%.
Is MacroGenics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MGNX is around 1.26 USD . This means that MGNX is currently overvalued and has a potential downside of -27.17%.
Is MGNX a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MGNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.4 | 96.5% |
| Analysts Target Price | 3.4 | 96.5% |
| ValueRay Target Price | 1.3 | -22.5% |
Last update: 2025-09-10 04:43
MGNX Fundamental Data Overview
CCE Cash And Equivalents = 176.5m USD (Cash And Short Term Investments, last quarter)
P/S = 0.6607
P/B = 2.3795
P/EG = 0.01
Beta = 1.638
Revenue TTM = 163.9m USD
EBIT TTM = -34.5m USD
EBITDA TTM = -26.9m USD
Long Term Debt = 159.8m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 5.12m USD (from shortTermDebt, last quarter)
Debt = 164.9m USD (Calculated: Short Term 5.12m + Long Term 159.8m)
Net Debt = -93.4m USD (from netDebt column, last quarter)
Enterprise Value = 97.8m USD (109.3m + Debt 164.9m - CCE 176.5m)
Interest Coverage Ratio = -37.60 (Ebit TTM -34.5m / Interest Expense TTM 917.0k)
FCF Yield = -73.72% (FCF TTM -72.1m / Enterprise Value 97.8m)
FCF Margin = -43.99% (FCF TTM -72.1m / Revenue TTM 163.9m)
Net Margin = -22.21% (Net Income TTM -36.4m / Revenue TTM 163.9m)
Gross Margin = 86.78% ((Revenue TTM 163.9m - Cost of Revenue TTM 21.7m) / Revenue TTM)
Tobins Q-Ratio = -0.08 (set to none) (Enterprise Value 97.8m / Book Value Of Equity -1.25b)
Interest Expense / Debt = 0.49% (Interest Expense 802.0k / Debt 164.9m)
Taxrate = 21.0% (US default)
NOPAT = -34.5m (EBIT -34.5m, no tax applied on loss)
Current Ratio = 5.25 (Total Current Assets 204.9m / Total Current Liabilities 39.0m)
Debt / Equity = 3.54 (Debt 164.9m / last Quarter total Stockholder Equity 46.6m)
Debt / EBITDA = -6.13 (Net Debt -93.4m / EBITDA -26.9m)
Debt / FCF = -2.29 (Debt 164.9m / FCF TTM -72.1m)
Total Stockholder Equity = 90.5m (last 4 quarters mean)
RoA = -14.83% (Net Income -36.4m, Total Assets 245.4m )
RoE = -40.24% (Net Income TTM -36.4m / Total Stockholder Equity 90.5m)
RoCE = -13.78% (Ebit -34.5m / (Equity 90.5m + L.T.Debt 159.8m))
RoIC = -38.12% (NOPAT -34.5m / Invested Capital 90.5m)
WACC = 3.43% (E(109.3m)/V(274.3m) * Re(8.03%)) + (D(164.9m)/V(274.3m) * Rd(0.49%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 81.82 | Cagr: 0.24%
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -72.1m)
EPS Correlation: -15.33 | EPS CAGR: -12.40% | SUE: -0.27 | # QB: 0
Revenue Correlation: -21.15 | Revenue CAGR: -20.46% | SUE: -0.28 | # QB: 0
Additional Sources for MGNX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle